Datroway Continues To Show Promising Tumor Responses As Part Of Combination Regimens In Patients With Early And Advanced Non-Small Cell Lung Cancer

RefinitivCzytanie zajmuje mniej niż 1 minutę

Daiichi Sankyo Co Ltd 4568:

DATROWAY® CONTINUES TO SHOW PROMISING TUMOR RESPONSES AS PART OF COMBINATION REGIMENS IN PATIENTS WITH EARLY AND ADVANCED NON-SMALL CELL LUNG CANCER
DAIICHI SANKYO CO LTD - PHASE 2 RESULTS SHOW POTENTIAL FOR DATROWAY PLUS DURVALUMAB

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Zaloguj się lub utwórz zawsze darmowe konto, aby przeczytać te wiadomości